20 results about "T cell immunity" patented technology

The invention discloses an RSV pre-F tripolymer protein combination and application thereof in preparation of bivalent RSV vaccines, and relates to the technical field of human vaccines. The vaccine is prepared by mixing an RSV-A subtype pre-F tripolymer protein and an RSV-B subtype pre-F tripolymer protein in equal mass, and matching with an aluminum hydroxide adjuvant with the concentration of 0.35 mg / 0.5 mL. A p27 fragment and a C-terminal esterification region of each of the two F proteins are deleted, the two F proteins are connected with F2 / F1 through GSGSGS, inter-chain disulfide bonds are introduced to S146C / N460C and A149C / Y458C sites respectively, intra-chain disulfide bonds are introduced to S155C / S290C sites respectively, and stable pre-F trimers are spontaneously assembled after secretion expression of CHO cells; the vaccine does not need to be freeze-dried, still keeps high purity and neutralizing epitope integrity after being stored at 37 DEG C for 28 days, can obviously induce neutralizing antibody and T cell immunity, and can be used for preventing various RSV-A / B infections.

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.

To provide various compositions and methods useful for the treatment of pancreatic cancer, such as pancreatic ductal adenocarcinoma (PDAC), and methods for activating pancreatic tissue-specific anti-tumor T cell immunity.SOLUTION: In certain embodiments, such methods comprise administration of IL33. In certain embodiments, such methods comprise administration of PD-1 and / or PD - L1 inhibitors.SELECTED DRAWING: None

The application provides a bicyclic compound with a structure shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a prodrug molecule thereof, a pharmaceutical composition and application. The compound provided by the application can activate CD137, enhance the immune function of cytotoxic T lymphocytes (CTL), enhance the memory function of CD8+ T cells and CD4+ T cells, can make the polarization of CD4+ T cells tilt to a state beneficial to cellular immunity, and can promote the multimerization of CD137, so that T cell immunity can be effectively activated, the volume of a primary tumor can be effectively reduced, and the compound can be used for inhibiting and treating tumors.

The application discloses a kind of sea fish mycobacterium infection mouse model based on T cell immune state difference and its construction method and application.The method under unified infection condition (bacterial amount 1×10 4 CFU, temperature 25 DEG C, time 4 weeks), respectively, constructs the infection model of congenital T cell immune deficiency nude mouse and the thymus pentapeptide processing mouse model of acquired T cell immune regulation, by comparing and analyzing the infection phenotype and pathological changes under different immune states, for the mechanism of T cell immunity in non-tuberculous mycobacterium infection, screening immune regulation treatment drug provides standardized experimental model.

A lipid compound containing a heteroaromatic ring structure and use thereof. Provided is use of a compound in the preparation of a lipid carrier. The compound is a compound represented by formula I, a pharmaceutically acceptable salt thereof, or a conjugate thereof. A liposome drug prepared using the lipid compound has a good adjuvant effect, and can effectively activate T cell immunity.

The invention provides a preparation method of a novel human / mouse cross-reactive anti-PD-1 candidate vaccine, and belongs to the technical field of candidate vaccine preparation. The candidate vaccine obtained by the preparation method can inhibit combination of PD-1 and PD-L1, can reactivate depleted T cells and break the tumor microenvironment of immunosuppression, and meanwhile, the epitope vaccine is combined with HBc VLPs to stimulate generation of strong T cell immunity, so that generation and development of tumor cells are inhibited in two aspects.

The invention discloses a method for enhancing the oxidative stress resistance of immune cells based on PRMT2 gene editing and application, and belongs to the technical fields of biology, biotechnology and immunotherapy. The invention further discloses a method for targeted knockout of protein arginine methyltransferase PRMT2 and application. The method can specifically, efficiently and stably silence expression of PRMT2. Experiments prove that the knockout of the PRMT2 can enhance the ROS removal capability of CD4 + T cells and CD8 + T cells and improve the oxidation resistance, so that the survival under oxidative stress and the generation of cell factors are enhanced; the killing activity of the CAR-T cells on tumor cells is effectively improved. The invention also discloses PRMT2 as an epigenetic inhibition factor of T cell immunity and a useful therapeutic target in infection and cancer immunotherapy. The method has a wide application prospect.

The application discloses a method for establishing a human alpha beta TCR and pMHC binding probability prediction model. The application designs a coding mode of TCR and pMHC amino acid sequences, trains a convolutional neural network through a machine learning method, and can predict the binding probability of TCR and pMHC. The prediction method has high prediction accuracy on unknown TCR, good generalization on single-chain TCR, double-chain TCR and single-double-chain mixed data, good prediction effect on CMV virus antigen-specific TCR, and is helpful for the research of T cell immunity.

This invention belongs to the interdisciplinary field of tumor immunotherapy and gene delivery, specifically relating to an aromatic hydrocarbon receptor blocking functional lipid nanoparticle, its preparation method, and its application. The ionizable lipid derived from the aromatic hydrocarbon receptor antagonist has the structure shown in formula (1): Formula (1), where x is an integer between 10 and 16, X is -N(Me)2 or -OH, and n = 0 or 1. This invention designs and synthesizes aromatic ionizable lipids that combine AHR antagonistic activity and nucleic acid delivery capability, constructing a functionalized LNP vector integrating AHR antagonism, nucleic acid delivery, and macrophage targeting. This vector can efficiently transfect macrophages in vivo and express CAR, while simultaneously blocking the AHR pathway in situ to reverse immunosuppression, enhancing antigen presentation, and activating T cell immunity. This fundamentally solves the core problem of the limited efficacy of existing CAR-M in vivo editing technology in solid tumors, especially gliomas.

The invention discloses a nanoparticle targeting HER2 breast cancer and application of the nanoparticle, a biological self-assembled helicobacter pylori ferritin nanoparticle (HPF) is used as a nano vaccine core, and a targeting dendritic cell WH peptide, an HER2 positive breast cancer target antigen HER2 extracellular domain and a T cell epitope immunogen AE37 peptide are covalently linked to the ferritin nanoparticle through a molecular glue system. The HER2 breast cancer targeting nanoparticles are obtained. The nanoparticles can be self-assembled, enhance immune response and simultaneously induce potent humoral immunity and T cell immunity, so that the anti-tumor effect is enhanced, and the nanoparticles can be applied to preparation of HER2 positive breast cancer vaccines.

The present application belongs to the technical field of immunotherapy, and particularly relates to a monkeypox virus antigen epitope peptide and application thereof. The present application aims to solve the technical problem that no T cell antigen epitope peptide for a monkeypox virus universal vaccine has been developed in the field of monkeypox virus. The technical scheme of the present application is a monkeypox virus antigen epitope peptide, the amino acid sequence of which is shown in SEQ ID No. 2. The antigen epitope peptide provided by the present application has strong immunogenicity and can induce antigen-specific CD8+ T cells; the antigen epitope peptide can be directly loaded into antigen presenting cells, can activate T cells, effectively induce T cell immunity, and can be used for research and development, preparation and drug research and development, and clinical treatment of a monkeypox virus universal vaccine.

The application discloses a kind of bioactive polyamino acid nanocomposites, preparation method and purposes, by condensation reaction synthesis hyaluronic acid-block-poly amphiphilic block copolymer, by hydrophobic, electrostatic, metal coordination etc. Interaction covers CD73 small molecule inhibitor APCP and PD1 / PD-L1 inhibitor S7911, preparation HA@APCP / S7911.HA@APCP / S7911 is enriched in tumor area by EPR effect, under the joint action of hyaluronidase and low pH in tumor area, realize the release of APCP and S7911 in tumor tissue.APCP is inhibited CD73 enzyme activity, restores the metabolism and activity of NK cell, starts NK cell immune response;S7911 is inhibited after release in tumor tissue PD-L1 and PD-1 binding, blocks immune checkpoint and starts T cell immunity, combined with radiotherapy to improve antitumor immune response, amplify the range of effective immune response, for promoting the combined effect of radioimmunotherapy provides a new way of thinking.

The invention discloses host-derived spermaceti capable of targeted enhancement of fish T cell immunity and application of spermaceti, and belongs to the technical field of microbial addition. According to the present invention, the cetobacter sobolifera strain is cetobacter sobolifera SH518, and the nucleotide sequence of the cetobacter sobolifera strain is represented by SEQ ID NO: 1; the invention also discloses an animal feed / probiotic feed. The animal feed / probiotic feed comprises a common feed and the spermaceti soxhlet; wherein no less than 107 CFU of the spermaceti is added into each gram of the common feed. According to the invention, the spermaceti soxhlet is added into the fish feed, so that the resistance of T cells of Nile tilapia to Edwardsiella fish killing infection is enhanced; the fish host-derived animal feed / probiotic feed provided by the invention is simple in preparation method, simple and convenient to operate, relatively low in cost and easy to popularize. The method has a wide application prospect.

This invention belongs to the field of immunotherapy technology, specifically relating to a monkeypox virus CD8+ T cell antigenic epitope peptide, its composition, and its application. The technical problem this invention aims to solve is that, currently, no universal monkeypox virus vaccine using a T cell antigenic epitope peptide has been developed. The technical solution of this invention is a monkeypox virus CD8+ T cell antigenic epitope peptide, the amino acid sequence of which is shown in SEQ ID No. 1. The antigenic epitope peptide provided by this invention possesses strong immunogenicity and can induce antigen-specific CD8+ T cells; it can be directly loaded onto antigen-presenting cells, activating T cells and effectively inducing T cell immunity. It can be used for the development, preparation, drug development, and clinical treatment of a universal monkeypox virus vaccine.

The present invention provides various compositions and methods useful for the treatment of pancreatic cancer, such as pancreatic ductal adenocarcinoma (PDAC), and methods for activating pancreatic tissue-specific anti-tumor T cell immunity. In some embodiments such methods involve administration of IL33. In some embodiments such methods involve administration of a PD-1 and / or PD-L1 inhibitor.

The invention relates to an mRNA (messenger ribonucleic acid) vaccine containing a proteasome targeting structural domain as well as a preparation method and application thereof. The invention provides a nucleic acid molecule comprising a coding sequence of at least one antigen peptide and a coding sequence of at least one proteasome targeting domain. The mRNA vaccine can increase the presentation rate of antigen peptide, enhance T cell immunity, and improve the killing effect on tumor cells and the immunocompetence on exogenous viruses.

The invention relates to the technical field of vaccines, and particularly discloses a preparation method and application of a tumor cell vaccine, the preparation method comprises the steps of collecting breast cancer cells in a growth index phase, preparing a cell suspension, performing radiation treatment, uniformly mixing the cells and the like, and single-time high-dose (40Gy) radiation is adopted as an inactivation mode; the completeness of a cell structure and the diversity of antigens can be kept to the greatest extent while the proliferation capacity of tumor cells is thoroughly destroyed. The prepared vaccine can strongly activate organism specific T cell immunity and significantly increase the number of IFN gamma < + > CD8 < + > T cells in peripheral blood and tumor local microenvironments, so that an immunosuppressive'cold tumor 'microenvironment is reversed to an immunoactivated'hot tumor' microenvironment, and resistance of breast cancer brain metastasis to immunotherapy is overcome.

This invention provides an ELISpot kit for detecting T-cell immunity in porcine epidemic diarrhea (PEDD) and its applications, belonging to the field of in vitro diagnostic technology. The hybridoma cell line 6E8-5G5, which secretes anti-porcine interferon-gamma monoclonal antibodies, can be used to prepare high-purity anti-porcine interferon-gamma monoclonal antibodies stably and in large quantities over a long period. Furthermore, an enzyme-linked immunospot (ELISpot) method based on PEDV N protein-specific IFN-γ is established. By detecting the level of specific T-cell immune responses against PEDV N protein after antigen stimulation, this provides technical support for the assessment of cellular immunity after PEDV infection or vaccine immunization.